Compounds > celecoxib
Page last updated: 2024-10-24

celecoxib and Ankylosing Spondylarthritis

celecoxib has been researched along with Ankylosing Spondylarthritis in 25 studies

Research Excerpts

ExcerptRelevanceReference
" SPARCC inflammation scores of the SIJ and spine decreased in the three groups, and significant differences were found between the combined group and the celecoxib group [between-group difference: -6."9.51Etanercept/celecoxib on improving MRI inflammation of active ankylosing spondylitis: A multicenter, open-label, randomized clinical trial. ( Cao, S; Chen, Z; Gu, J; Jin, O; Kong, Q; Li, Q; Liao, Z; Lin, Z; Lv, Q; Pan, Y; Qi, J; Tu, L; Wang, X; Wei, Q; Ye, Z; Yu, Q; Zhao, M, 2022)
"The aim of the study is to assess the effects of celecoxib and sulfasalazine on the risk of coronary artery disease (CAD) in patients with ankylosing spondylitis (AS)."7.83Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. ( Chiou, JY; Leong, PY; Li, TY; Wang, YH; Wei, JC; Wu, LC; Yeo, KJ, 2016)
"Celecoxib would appear to be a useful option for therapy in patients at high risk for NSAID-induced GI toxicity, or in those responding suboptimally to or intolerant of NSAIDs."6.47Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. ( McCormack, PL, 2011)
" SPARCC inflammation scores of the SIJ and spine decreased in the three groups, and significant differences were found between the combined group and the celecoxib group [between-group difference: -6."5.51Etanercept/celecoxib on improving MRI inflammation of active ankylosing spondylitis: A multicenter, open-label, randomized clinical trial. ( Cao, S; Chen, Z; Gu, J; Jin, O; Kong, Q; Li, Q; Liao, Z; Lin, Z; Lv, Q; Pan, Y; Qi, J; Tu, L; Wang, X; Wei, Q; Ye, Z; Yu, Q; Zhao, M, 2022)
"Celecoxib was neutral regarding CVD risk in AS patients."5.46Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study. ( Chen, CH; Chiou, JY; Leong, PY; Li, YC; Ma, CM; Tam, HW; Wang, YH; Wei, JC; Yeo, KJ, 2017)
"The aim of the study is to assess the effects of celecoxib and sulfasalazine on the risk of coronary artery disease (CAD) in patients with ankylosing spondylitis (AS)."3.83Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. ( Chiou, JY; Leong, PY; Li, TY; Wang, YH; Wei, JC; Wu, LC; Yeo, KJ, 2016)
"The Bath ankylosing spondylitis disease activity index (BASDAI), nocturnal back pain (NBP), total back pain (TBP), patient global disease activity (PGDA), the Bath ankylosing spondylitis functional index (BASFI), and the Bath ankylosing spondylitis metrology index (BASMI) were measured at each time point."2.87Clinical Efficacy of Modified Yanghe Decoction in Ankylosing Spondylitis: A Randomized Controlled Trial. ( Wang, Y; Xiao, X, 2018)
"Both celecoxib treatment groups were non-inferior to diclofenac."2.82Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients. ( Essex, MN; Li, C; Park, PW; Walker, C, 2016)
"Celecoxib 400 mg was as effective as naproxen; however, naproxen was more effective than celecoxib 200 mg."2.72Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. ( Barkhuizen, A; Coombs, J; Robbins, J; Steinfeld, S; West, C; Zwillich, S, 2006)
" All patients began treatment with celecoxib, at a starting dosage of 100 mg twice daily; patients could increase this dosage to 200 mg twice daily or could switch to another NSAID while maintaining the same treatment strategy."2.71Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. ( Béhier, JM; Calin, A; Dougados, M; Heijde, Dv; Landewé, R; Olivieri, I; Wanders, A; Zeidler, H, 2005)
"Celecoxib would appear to be a useful option for therapy in patients at high risk for NSAID-induced GI toxicity, or in those responding suboptimally to or intolerant of NSAIDs."2.47Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. ( McCormack, PL, 2011)
"to review the safety of celecoxib in ankylosing spondylitis treatment."2.44The safety of celecoxib in ankylosing spondylitis treatment. ( Poddubnyy, DA; Sieper, J; Song, IH, 2008)
"Renal complications in ankylosing spondylitis (AS) were rarely observed, and proteinuria associated with AS can be seen often due to amyloidosis in this kind of complications, while membranous nephropathy (MN) is seldom considered."1.46Membranous nephropathy in a patient with ankylosing spondylitis: A case report. ( Chen, R; Hao, C; Lai, L; Li, F; Liu, S; Xie, Q; Xue, J; Zhang, L, 2017)
"Celecoxib was neutral regarding CVD risk in AS patients."1.46Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study. ( Chen, CH; Chiou, JY; Leong, PY; Li, YC; Ma, CM; Tam, HW; Wang, YH; Wei, JC; Yeo, KJ, 2017)
" Our objective was to estimate and compare rates of gastrointestinal, renovascular, and cardiovascular adverse events in patients exposed to etoricoxib, celecoxib, or nonselective NSAIDs or totally unexposed to NSAIDs."1.42Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study. ( Askling, J; Jacobsson, LT; Jakobsen, AK; Kristensen, LE; Nilsson, F, 2015)

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (48.00)29.6817
2010's11 (44.00)24.3611
2020's2 (8.00)2.80

Authors

AuthorsStudies
Tu, L1
Zhao, M1
Wang, X2
Kong, Q1
Chen, Z1
Wei, Q1
Li, Q1
Yu, Q1
Ye, Z1
Cao, S1
Lin, Z1
Liao, Z1
Lv, Q1
Qi, J1
Jin, O1
Pan, Y1
Gu, J1
Zhang, Y1
Ning, C1
Zhou, H1
Yan, Y1
Liu, F1
Huang, Y1
Proft, F1
Muche, B1
Listing, J1
Rios-Rodriguez, V1
Sieper, J3
Poddubnyy, D1
Chen, R1
Li, F1
Xie, Q1
Xue, J1
Lai, L1
Liu, S1
Zhang, L1
Hao, C1
Wang, Y1
Xiao, X1
Zheng, Y1
Gu, M1
Shi, D1
Li, M1
Ye, L1
Kristensen, LE1
Jakobsen, AK1
Askling, J1
Nilsson, F1
Jacobsson, LT1
Walker, C1
Essex, MN1
Li, C1
Park, PW1
Wu, LC1
Leong, PY2
Yeo, KJ2
Li, TY1
Wang, YH2
Chiou, JY2
Wei, JC2
Tam, HW1
Chen, CH1
Li, YC1
Ma, CM1
Poddubnyy, DA1
Song, IH1
Benhamou, M1
Gossec, L1
Dougados, M4
Jansen, JP1
Gaugris, S1
Choy, EH1
Ostor, A1
Nash, JT1
Stam, W1
McCormack, PL1
Toussirot, E1
Wendling, D1
Ward, MM1
Wanders, A1
Heijde, Dv1
Landewé, R1
Béhier, JM2
Calin, A2
Olivieri, I2
Zeidler, H2
Krüger, K1
Zochling, J1
Bohl-Bühler, MH1
Baraliakos, X1
Feldtkeller, E1
Braun, J1
Barkhuizen, A1
Steinfeld, S1
Robbins, J1
West, C1
Coombs, J1
Zwillich, S1
Tubach, F1
Pham, T1
Skomsvoll, JF1
Mikkelsen, K1
Bjørneboe, O1
Ravaud, P1
Kvien, TK1
Klopsch, T1
Richter, M1
Kapelle, A1
Rudwaleit, M1
Schwank, S1
Regourd, E1
May, M1
Jolchine, I1
van der Heijde, D1
Herman, H1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis[NCT01934933]Phase 4150 participants (Actual)Interventional2014-09-24Completed
COmparison of the Effect of Treatment With NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine Over Two Years in Patients With ankyLosing Spondylitis: a Randomized Controlled Multicentre Trial[NCT02758782]Phase 4156 participants (Actual)Interventional2016-09-30Completed
A Single Center, Randomized, Double-blind, Placebo-controlled 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee Pain.[NCT01619150]Phase 239 participants (Actual)Interventional2012-07-31Completed
Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial[NCT00715091]Phase 4180 participants (Actual)Interventional2008-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

4 reviews available for celecoxib and Ankylosing Spondylarthritis

ArticleYear
The safety of celecoxib in ankylosing spondylitis treatment.
    Expert opinion on drug safety, 2008, Volume: 7, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibit

2008
Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
    Drugs, 2011, Dec-24, Volume: 71, Issue:18

    Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Hum

2011
Recent progress in ankylosing spondylitis treatment.
    Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:1

    Topics: Celecoxib; Controlled Clinical Trials as Topic; Diphosphonates; Drug Therapy; Humans; Methotrexate;

2003
[The efficacy of selective Cox-2-inhibitors in comparison with conventional NSAIDs].
    MMW Fortschritte der Medizin, 2005, Aug-04, Volume: 147, Issue:31-32

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis,

2005

Trials

11 trials available for celecoxib and Ankylosing Spondylarthritis

ArticleYear
Etanercept/celecoxib on improving MRI inflammation of active ankylosing spondylitis: A multicenter, open-label, randomized clinical trial.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Adult; Celecoxib; Etanercept; Humans; Inflammation; Magnetic Resonance Imaging; Spondylitis, Ankylos

2022
Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two yea
    BMJ open, 2017, 06-10, Volume: 7, Issue:6

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Celecoxib; Disease Progressi

2017
Clinical Efficacy of Modified Yanghe Decoction in Ankylosing Spondylitis: A Randomized Controlled Trial.
    Medical science monitor : international medical journal of experimental and clinical research, 2018, May-08, Volume: 24

    Topics: Celecoxib; Drugs, Chinese Herbal; Female; Humans; Male; Spondylitis, Ankylosing; Sulfasalazine; Trea

2018
Tomography-guided palisade sacroiliac joint radiofrequency neurotomy versus celecoxib for ankylosing spondylitis: a open-label, randomized, and controlled trial.
    Rheumatology international, 2014, Volume: 34, Issue:9

    Topics: Adult; Back Pain; Catheter Ablation; Celecoxib; China; Cyclooxygenase 2 Inhibitors; Female; Humans;

2014
Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients.
    The Journal of international medical research, 2016, Volume: 44, Issue:3

    Topics: Celecoxib; Diclofenac; Endpoint Determination; Humans; Norway; Spondylitis, Ankylosing; Treatment Ou

2016
Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein.
    Rheumatology (Oxford, England), 2010, Volume: 49, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; C-Reactive Protein; Celecoxib; Cyclooxyg

2010
Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial.
    Arthritis and rheumatism, 2005, Volume: 52, Issue:6

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Disease Progre

2005
Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis.
    The Journal of rheumatology, 2006, Volume: 33, Issue:9

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Dose-Response Relationship, Drug; Double-

2006
Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis.
    Arthritis and rheumatism, 2006, Dec-15, Volume: 55, Issue:6

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Female; Follow-Up Studies; He

2006
Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.
    Annals of the rheumatic diseases, 2008, Volume: 67, Issue:3

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibito

2008
Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.
    Arthritis and rheumatism, 2001, Volume: 44, Issue:1

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Female; Gastro

2001

Other Studies

10 other studies available for celecoxib and Ankylosing Spondylarthritis

ArticleYear
Interleukin-1β, interleukin-6, and interleukin-17A as indicators reflecting clinical response to celecoxib in ankylosing spondylitis patients.
    Irish journal of medical science, 2021, Volume: 190, Issue:2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Female; Humans; Interleukin-17; Interleuk

2021
Membranous nephropathy in a patient with ankylosing spondylitis: A case report.
    Medicine, 2017, Volume: 96, Issue:43

    Topics: Adalimumab; Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Glomerulonephritis, Membranous; H

2017
Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study.
    Arthritis care & research, 2015, Volume: 67, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-

2015
Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study.
    Medicine, 2016, Volume: 95, Issue:36

    Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Case-Control Studies; Celecoxib; Coronary Artery Dis

2016
Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study.
    International journal of rheumatic diseases, 2017, Volume: 20, Issue:3

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib

2017
Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
    PharmacoEconomics, 2010, Volume: 28, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Celecoxib; Cost-Benefit Analysis; Cyclooxyge

2010
Prospects for disease modification in ankylosing spondylitis: do nonsteroidal antiinflammatory drugs do more than treat symptoms?
    Arthritis and rheumatism, 2005, Volume: 52, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Celecoxib; Clinical Trials as Topic;

2005
Celecoxib approved for pain relief for AS.
    Health news (Waltham, Mass.), 2005, Volume: 11, Issue:11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Humans; Pain; Pyrazoles; Spondylitis, Ankylosing

2005
Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis--a population-based survey.
    Clinical rheumatology, 2006, Volume: 25, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies;

2006
[Effective also in Bechterew disease].
    MMW Fortschritte der Medizin, 2007, Jun-21, Volume: 149, Issue:25-26

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Combined Modality Ther

2007